logo-loader
Destiny Pharma PLC

Destiny Pharma PLC - Grant of share options

RNS Number : 7264J
Destiny Pharma PLC
23 December 2020
 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of share options

Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it has granted options ("Options") over 1,985,620 new ordinary shares of £0.01 each in the Company (representing 3.32 per cent. of the Company's issued share capital) to certain employees of the Company, including the Directors and PDMR named below.

 

Name

Position

Options Issued

2018 LTIP scheme

Options Issued

2020 LTIP

scheme

Total Options

Held

Post Issue

Neil Clark

Chief Executive Officer

205,695

353,692

1,103,692

 

Shaun Claydon

 

 

William Love

 

Jesus Gonzalez

Chief Financial Officer

 

 

Chief Scientific Officer

 

Chief Medical Officer and PDMR

125,000

 

 

125,000  

 

115,000

261,538

 

 

240,511

 

219,184

661,538

 

1,130,905

449,184

 

 

The first tranche of Option awards have been made under the Destiny Pharma Employee Long Term Incentive Plan 2018 approved by the Company on 25 January 2018 for EMI and non-tax advantage options. The Options have been granted at a price of £0.01 per Ordinary Share,  will vest on the third anniversary of the date of grant and are exercisable for ten years thereafter. These share option awards were delayed in 2019/20 due to constraints related to the total number of shares in issue.

 

The second tranche of Options represent awards granted under the new Destiny Pharma plc 2020 Long Term Incentive Plan approved by the Company on 22 December 2020 for EMI and non-tax advantaged options. The Options have been granted with a nominal exercise price and will vest subject to the achievement of Total Shareholder Return measures over a three-year performance period.

 

Enquiries:

Destiny Pharma plc

+44 (0) 1273 704 440

Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)

 

finnCap Limited - Nominated Adviser and Joint Broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)

 

WG Partners LLP - Joint Broker

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig

 

Optimum Strategic Communications

+44 (0) 203 174 1789

Mary Clark / Shabnam Bashir / Manel Mateus

 

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

 

For further information, please visit https://www.destinypharma.com

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Neil Clark

2.               

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.

 

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.

c)

Price(s) and volume(s)

1 pence exercise price per Ordinary Share

 559,387 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

23 December 2020

f)

Place of the transaction

London Stock Exchange, AIM Market

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Shaun Claydon

2.               

Reason for the Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.

 

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.

c)

Price(s) and volume(s)

1 pence exercise price per Ordinary Share

386,538 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

23 December 2020

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bill Love

2.               

Reason for the Notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.

 

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.

c)

Price(s) and volume(s)

1 pence exercise price per Ordinary Share

365,511 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

23 December 2020

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jesus Gonzalez

2.               

Reason for the Notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.

 

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan.

c)

Price(s) and volume(s)

1 pence exercise price per Ordinary Share

334,184 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

23 December 2020

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUORSRRWUUUAA
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma's nasal spray project already delivering "more than hoped for"

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than hoped for" and...

on 2/5/23

7 min read